BridgeBio Pharma (FRA:2CL) Short Percentage of Float


FRA:2CL BridgeBio Pharma Inc FRA:2CL
66 GF Score
Price €59.93
GF Value €124.34
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is BridgeBio Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:2CL vs EXEL, IONS, SMMT: Short Percentage of Float Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Short Percentage of Float falls into.


FRA:2CL
66GF Score
BridgeBio Pharma Inc FRA:2CL
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €59.93 is trading 51.8% below its estimated GF Value™ of €124.34. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Short Percentage of Float:
  • GF Value™: €124.34 vs. price of €59.93 (51.8% below fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score

Get the complete analysis for FRA:2CL

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€59.93
Price
€124.34
GF Value